Epidermal growth factor treatment has protective effects on the integrity of the blood‑brain barrier against cerebral ischemia injury in bEnd3 cells

Introduction

The blood-brain barrier (BBB) is a specialized tissue that restricts certain substances from entering the brain and protects normal neuronal function (1). The BBB is composed of cerebral endothelial cells, astrocytes and pericytes (2). Brain endothelial cells form the structural basis of the BBB and are characterized by the presence of tight junctions (TJs). TJs are composed of multiple protein complexes, including occludin, claudin-5 and TJ protein-1 (ZO-1) (3). Under normal conditions, TJs seal the gaps between endothelial cells and prevent the paracellular movement of molecules, wherein pathological insults caused by neurological disorders may lead to TJ disruption and BBB leakage, aggravating brain damage (4).

Ischemic stroke, which accounts for ~85% of all cases of stroke, is one of the most common diseases worldwide with a high disability and mortality rates (5). The obstruction of blood vessels reduces oxygen and glucose supply to the cerebral tissue and results in an energy failure, which triggers a cascade of events, including the release of proinflammatory cytokines, elevated levels of reactive oxygen species (ROS) and the activation of matrix metalloproteinases (MMPs) (6). These lead to TJ protein degradation, which can be exacerbated by thrombolytic therapy (7). Enhanced BBB permeability induces the occurrence of deleterious complications, including brain edema and hemorrhage transformation (8). Numerous compounds, including α-lipoic acid, ruscogenin and calycosin-7-O-β-D-glucoside, were reported to protect the ischemia-induced BBB injury through decreasing the generation of ROS or inhibiting the activity of MMPs (9–11). Therefore, targeting BBB integrity suggests a promising therapeutic approach for ischemic stroke treatment.

The epidermal growth factor (EGF) is a potent mitogen for mediating neuronal proliferation and inducing central nerve system (CNS) progenitor cells to produce astrocytes and neurons (12). EFG bioavailability in the brain is ensured through production in the CNS by glial cells and neurons and through uptake from the peripheral circulation (13). EGF has been examined as a neurotrophic factor against stroke in animal models in vivo (14). It also reduces BBB permeability by activating the EGF receptor and the downstream mitogen-activated protein kinase (MAPK) signaling pathway (15,16). However, further investigation is required as to whether EGF may preserve BBB integrity against ischemic insult.

In the current study, an in vitro oxygen-glucose deprivation (OGD) model was established based on bEnd3 cells, to explore the benefit of EGF on BBB integrity and protection against ischemic injury. TJ protein expression levels were measured in addition to endothelial permeability and cell viability, to demonstrate the protective effect of EGF against ischemic injury by improving BBB integrity.

Materials and methods

Materials

bEnd3 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin solution and Hank's balanced salt solution (HBSS) were purchased from HyClone (GE Healthcare Life Sciences, Logan, UT, USA). Lucifer yellow (LY) was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Rabbit claudin-5 antibody (cat. no. ab15106) was obtained from Abcam (Cambridge, UK). Rabbit ZO-1 antibody (cat. no. 21773-1-AP) was purchased from ProteinTech Group, Inc. (Chicago, IL, USA). Mouse GAPDH antibody (cat. no. C1312), horseradish peroxide (HRP)-conjugated goat anti-rabbit (cat. no. C1309) and anti-mouse (cat. no. C1308) IgG antibodies, the Cell Counting kit-8 (CCK8) and the bicinchoninic acid (BCA) assay kit were obtained from Applygen Technologies, Inc. (Beijing, China). Polyvinylidene difluoride (PVDF) membranes and the chemiluminescent HRP substrate (cat. no. WBKLS0100) were purchased from EMD Millipore (Billerica, MA, USA). The 24-well polyester Transwell inserts (pore size, 0.4 µM; diameter, 6.5 mm) were obtained from Corning Inc. (Corning, NY, USA).

Cell culture and treatment

bEnd3 cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C with 5% CO2 at a density of 3×105/well in six-well plates. After 24 h, confluent bEnd3 cells were placed with glucose-free and serum-free DMEM (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) and incubated in an anaerobic chamber (1% O2) flushed with 95% N2 and 5% CO2 for 4, 6 and 12 h (10). For reoxygenation (RO), cells were subsequently returned to normoxic conditions and incubated in glucose-containing and serum-free standard DMEM for 24 h. For the control group, the bEnd3 cells were incubated in glucose-containing and serum-free standard DMEM medium for the same period of time under normoxic conditions for the entire duration of the experiment. EGF-administered groups were treated with mouse EGF (250 ng/ml; ProteinTech Group, Inc.) diluted with standard DMEM following a 4-h OGD period at the beginning of the RO process.

Cell viability

bEnd3 cells (5×103/well) were seeded in 96-well plates and incubated for 24 h prior to OGD treatment for 4, 6 and 12 h as detailed above. A total of 10 µl CCK8 solution was subsequently added to each well and incubated for 1 h at 37°C. Absorbance was measured at 450 nm using a plate reader. Changes in cell viability were expressed compared with respective normoxic groups.

Western blot analysis

Cells were harvested following RO and homogenized in radioimmunoprecipitation assay buffer (Applygen Technologies, Inc.) containing the protease inhibitor. The protein concentration was determined by BCA assays. Proteins (40 µg) were separated on 12 and 8% SDS-PAGE gels for claudin-5 and ZO-1 analysis, respectively, and transferred to PVDF membranes. Following blocking with 5% non-fat milk for 1 h at room temperature, membranes were incubated with primary antibodies of claudin-5 (dilution, 1:1,000), ZO-1 (dilution, 1:1,000) and GAPDH (dilution, 1:2,000) at 4°C overnight, followed by incubation with secondary antibodies (dilution, 1:5,000) for 1 h at room temperature. Protein bands were visualized by chemiluminescence detection using a FluorChem FC2 system (Cell Biosciences, Inc., Santa Clara, CA, USA) and band densities were quantified by Image J (version 1.43; National Institute of Health, Bethesda, MD, USA). Bands were normalized to GAPDH and expressed in comparison with respective normoxic controls.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis

Total RNA was extracted from bEnd3 cells following RO using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol and quantified using a spectrophotometer. RNA (1 µg) was reverse-transcribed into cDNA using the PrimeScript™ RT reagent kit with gDNA Eraser (Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocol. qPCR was performed using the SYBR Premix Ex Taq II kit (Takara Bio, Inc.) according to the manufacturer's protocol using the following thermocycling conditions: 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec, 60°C for 20 sec and 72°C for 30 sec. Primer sequences were as follows: Claudin-5, forward, 5′-GTTAAGGCACGGGTAGCACT-3′ and reverse, 5′-TACTTCTGTGACACCGGCAC-3′; ZO-1, forward, 5′-AAGTTGGCAAGAGAGGAGCC-3′ and reverse, 5′-CAACCGCATTTGGCGTTACA-3′; GAPDH, forward, 5′-ACGTCTGCCACGATAACACC-3′ and reverse, 5′-CTGCATGATTGGGTCACGTC-3. GAPDH was used as internal control and mRNA expression levels were quantified using the 2−ΔΔCq method (17).

Permeability assay

bEnd3 cells (3.3×104/well) were seeded in Transwell inserts and incubated for 5 days at 37°C prior to performing the OGD. Following 4 h of OGD and 24 h of RO treatment, LY (50 µM) dissolved in HBSS was added to the upper compartment and the lower compartment contained blank HBSS. At indicated time points (15, 30, 45 and 60 min), samples were taken from the lower compartment and analyzed using a plate reader (excitation, 430 nM; emission, 540 nM). The permeability coefficient (Papp) was measured by the following equation: Papp=A/(SxC0), where A represents the rate of drug accumulated at the lower compartment, S represents the membrane area and C0 is the initial drug concentration at the upper compartment.

Statistical analysis

Data are expressed as the mean ± standard deviation, representative of three replicates. Differences between groups were assessed by one-way analysis of variance followed by Tukey's post hoc test using SPSS (version 19.0; IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of OGD on TJ protein expression and cell viability

Claudin-5 is a key TJ protein that determines BBB permeability and integrity (18). As an indicator of ischemia-induced BBB disruption, claudin-5 expression was measured in bEnd3 cells, following exposure to OGD for various periods and 24 h RO. As presented in Fig. 1A, 4, 6 and 12 h OGD exposure resulted in a time-dependent decrease in claudin-5 protein expression compared with the normoxic controls. Cell viability analysis revealed no significant difference between the control and treatment groups following 4 and 6 h OGD exposure. In contrast, 12 h OGD exposure revealed a significant reduction of 45% in cell viability compared with the normoxic control (P<0.01; Fig. 1B).

Figure 1. Effects of OGD on claudin-5 protein expression and cell viability in bEnd3 cells. Cells were exposed to 4, 6 and 12 h of OGD followed by 24 h reoxygenation. (A) Claudin-5 protein expression measured by western blot analysis. (B) Cell viability determined by cell counting kit-8 assays. **P<0.01 vs. Con. ODG, oxygen-glucose deprivation; Con, normoxic control.

EGF attenuates OGD-induced BBB disruption

To identify protective effects of EGF on ischemia-induced BBB disruption, EGF was added to bEnd3 cells immediately following 4 h OGD exposure prior to RO and subsequently TJ protein expression levels were measured. In addition, endothelial cell permeability of LY and cell viability were determined. As presented in Fig. 2A and B, 4 h OGD exposure caused a significant decrease in claudin-5 and ZO-1 protein expression compared with the control (71.3 and 41.2%, respectively; P<0.01), which was significantly ameliorated by EGF treatment (P<0.01 vs. OGD). However, the differences in the decrease of claudin-5 levels between the same groups in Fig. 1 (54.2%) and Fig. 2 (71.3%) may be attributed to the differential cell growth status and density prior to performing OGD in separate experiments. A significant decrease in mRNA expression by 61.5 and 52.1% was observed for claudin-5 and ZO-1 in the OGD group compared with the control group (P<0.01), while EGF significantly reversed this decrease (P<0.05; Fig. 2C). In addition, EGF treatment significantly attenuated an increase in endothelial permeability of LY following 4 h OGD exposure (P<0.05 vs. OGD; Fig. 2D). No significant differences were observed in cell viability following EGF treatment compared with the OGD and normoxic control groups (P>0.05; Fig. 2E). Results indicated that the protective effect of EGF on BBB integrity may be via enhancing TJ protein expression and decreasing BBB permeability.

Figure 2. Effects of EGF on OGD-induced blood-brain barrier disruption in vitro. bEnd3 cells were exposed to OGD for 4 h and treated with EGF (250 ng/ml) prior to 24 h reoxygenation. Protein expression of (A) claudin-5 and (B) ZO-1 was determined by western blotting. (C) mRNA expression levels of claudin-5 and ZO-1 were evaluated using reverse transcription-quantitative polymerase chain reaction assays. (D) Endothelial permeability of LY was determined by Transwell assay and (E) cell viability was evaluated using cell counting kit-8 analysis. ##P<0.01 vs. Con; *P<0.05 and **P<0.01 vs. OGD. EGF, epidermal growth factor; ODG, oxygen-glucose deprivation; Con, normoxic control; LY, Lucifer yellow; E250, 250 ng/ml EGF treatment; Papp, permeability coefficient.

Discussion

Cerebral endothelial cells are a crucial component of the neurovascular unit and are implicated in many biological functions, including regulating vascular tone, providing trophic support for neurons and mediating inflammatory responses (9). They also contribute to BBB integrity by forming TJs, which block the paracellular flux (19). However, neurological disorders, including ischemic stroke, damage the cerebral endothelium leading to TJ dysfunction and BBB leakage, which are associated with complications, including brain edema and hemorrhage transformation (20). Therefore, there is an increasing interest in the protection of BBB integrity in stroke therapy (21).

The current study established an in vitro OGD model using the mouse brain microvascular endothelial cell line bEnd3 to mimic clinical ischemic stroke (22,23). An increasing OGD exposure duration was observed to be associated with a decrease in claudin-5 protein expression, indicating a potential ischemia-induced BBB disruption. A 4 h OGD exposure was selected for subsequent studies as it closely reflected the limited therapeutic window of 4.5 h in ischemic stroke in a clinical setting (6). However, in contrast to previous studies, this duration of OGD exposure had no significant effect on cell viability. This may be attributed to the difference in oxygen levels during the OGD period, 1% here compared with 0.3% previously reported (24), which resulted in varying cell damage in the RO period.

The BBB phenotype of cerebral endothelial cells is regulated by the release of cytokines in the microenvironment (25). Glial-derived neurotrophic factor and basic fibroblast growth factor enhance TJ function, while proinflammatory cytokines, including interleukin-6 and tumor necrosis factor-α may damage BBB integrity (26). EGF has been reported to preserve endothelial integrity and protect TJ disruption against hydrogen peroxide (27). In the present study it was demonstrated that EGF upregulated the mRNA and protein expression of claudin-5 and ZO-1 and reduced the endothelial cell permeability of LY against ischemic insults in vitro. As OGD and EGF exerted no significant influence on cell viability, according to the conditions evaluated in the present study, the protective effect of EGF on BBB integrity was mainly attributed to the elevation in TJ protein expression levels. Furthermore, MAPK and protein kinase B (Akt) signaling, downstream pathways of EGF, serve important roles in cell proliferation, survival and apoptosis (28). Their activation participates in the regulation of TJ protein expression and TJ function (29–31). Therefore, further investigation on whether EGF preserves BBB integrity against ischemic stroke by modulating the MAPK and Akt signaling pathways is required. Additionally, electron microscopy is an effective approach for observing BBB disruption at the ultrastructure level (32) and this method maybe explored in future BBB studies.

In summary, EGF ameliorated TJ protein degradation and inhibited increased BBB permeability induced by OGD treatment in bEnd3 cells. The aforementioned findings indicated a beneficial effect of EGF on BBB integrity against ischemic insult.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81703376) and the Youth Foundation of Beijing Tiantan Hospital (grant no. 2016-YQN-11).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

SY and ZZ designed the study. SY performed all experiments. SY and HJ interpreted the data and drafted the manuscript. ZZ critically reviewed and revised the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References